《病毒疫苗研發(fā)新趨勢及整體解決方案-呼吸道合胞病毒、流感病毒、皰疹病毒等》

新型疫苗技術(shù)平臺概述及整體解決方案

-呼吸道合胞病毒、流感病毒、皰疹病毒等北京義翹神州科技股份有限公司義翹神州CONTENT新型疫苗技術(shù)平臺概述1重要病毒疫苗的概述及開發(fā)挑戰(zhàn)2整體解決方案及相關(guān)案例分享3義翹神州新型疫苗技術(shù)平臺概述01義翹神州新型疫苗定義新型疫苗其有別于傳統(tǒng)常規(guī)疫苗按制備工藝分類基于蛋白的疫苗基于病毒載體疫苗基于核酸的疫苗Figure-PMC()傳統(tǒng)新型義翹神州新型疫苗定義蛋白質(zhì)亞單位疫苗病毒樣顆粒疫苗基于蛋白的疫苗只含有病原體中具有抗原性的部分，也就是可以誘發(fā)免疫反應(yīng)的抗原。義翹神州基于病毒載體的疫苗是一種利用病毒載體將合成抗原的遺傳物質(zhì)傳送至人體宿主細(xì)胞的疫苗?；诤怂岬囊呙鐚⒕幋a某種抗原蛋白的外源基因（DNA或RNA）直接導(dǎo)入動物體細(xì)胞內(nèi)，并通過宿主細(xì)胞的表達(dá)系統(tǒng)合成抗原蛋白，以達(dá)到預(yù)防和治療疾病的目的。ADVVSVLVsPoxvirusDNARNA新型疫苗技術(shù)平臺簡介——VLP/10.1016/B978-0-323-85662-1.00004-5

義翹神州佐劑穩(wěn)定性AVisualAidtoViralInfectionandVaccineProduction-LozierInstitute義翹神州新型疫苗技術(shù)平臺簡介——病毒載體疫苗載體類型預(yù)先存在的免疫安全性Doi:

10.1016/j.ymthe.2022.02.016義翹神州序列設(shè)計遞送系統(tǒng)新型疫苗技術(shù)平臺簡介——基于核酸的疫苗生產(chǎn)系統(tǒng)宿主疾病疫苗名稱（制造商）監(jiān)管批準(zhǔn)抗原疫苗類型酵母S.cerevisiaeHBVEngerix?-B(GSK)1989年FDAHBsAgVLPS.cerevisiaeHPVGardasil-9?

(Merck&Co.)2014年FDA2015EMAL1VLP昆蟲細(xì)胞HighFive?HPVCervarix?

(GSK)2007EMA2009FDAL1VLPExpresSF+?流感FlublokQuadrivalent?/Supemtek?

(SanofiPasteur)??2016年FDA2020年EMAHAquadrivalentSubunit哺乳動物細(xì)胞CHOVZVShingrix?

(GSK)2017年FDA2018年EMAgESubunitCHORSVArexvy?

(GSK)2023年FDAPre-FSubunit用于人類的重組蛋白疫苗：義翹神州病毒載體疫苗病毒載體疾病疫苗名稱（制造商）監(jiān)管批準(zhǔn)抗原VSV埃博拉Ervebo?(Merck&Co.)2019年FDAZEBOV-GPADV26（第一劑）埃博拉Zabdeno?（JNJ）2020年EMAZEBOV-GP

ModifiedVacciniaAnkaraBavarianNordicVirus（第二劑）埃博拉Mvabea?（JNJ）2020年EMA

ZEBOV-GPChimpanzeeadenovirusSARS-Cov-2Vaxzevria?

（AstraZeneca）2021年

EMAspikeproteinADV5SARS-Cov-2克威莎（CanSinoBiologics）2021年NMPAspikeproteinADV26SARS-Cov-2Ad26.COV2.S（JNJ）2021年FDAspikeprotein義翹神州疾病疫苗名稱（制造商）監(jiān)管批準(zhǔn)抗原SARS-Cov-2Comirnaty?(Pfizer/BioNtech)2021年

FDAspikeproteinSARS-Cov-2Spikevax?（Moderna）2022年FDAspikeprotein基于核酸的疫苗義翹神州重要病毒疫苗的概述及開發(fā)挑戰(zhàn)02義翹神州InfluenzaVirus-病毒抗原簡介蛋白在流感病毒生活周期中的作用應(yīng)用HA(血凝素)宿主細(xì)胞膜上的唾液酸受體相結(jié)合，協(xié)助病毒包膜與宿主細(xì)胞膜相互融合；凝血作用

流感疫苗NA(神經(jīng)氨酸酶)水解唾液酸受體，促進(jìn)成熟病毒顆粒釋放通用流感疫苗NP(核蛋白)與流感遺傳物質(zhì)結(jié)合，參與病毒基因復(fù)制、轉(zhuǎn)錄、翻譯；維持病毒基因穩(wěn)定性

通用流感疫苗M蛋白保護(hù)病毒核心，維護(hù)病毒空間結(jié)構(gòu)

通用流感疫苗義翹神州InfluenzaVirus-疫苗進(jìn)展目前，全球批準(zhǔn)的流感疫苗主要有三種類型：滅活疫苗、減毒活疫苗和重組蛋白疫苗。每年，WHO會公布下一流感季的疫苗株組成，含有甲型H1N1和甲型H3N2流感病毒以及乙型流感病毒的成分，以“三價”或“四價”制劑生產(chǎn)。Recommendationsannouncedforinfluenzavaccinecompositionforthe2023-2024northernhemisphereinfluenzaseasonRecommended

composition

of

influenza

virus

vaccines

for

use

in

the

2023-2024

northern

hemisphere

influenza

season

()

TheWHOrecommendsthatquadrivalentvaccinesforuseinthe2023-2024northernhemisphereinfluenzaseasoncontainthefollowing:Egg-basedvaccinesanA/Victoria/4897/2022(H1N1)pdm09-likevirus;anA/Darwin/9/2021(H3N2)-likevirus;andaB/Austria/1359417/2021(B/Victorialineage)-likevirus;andaB/Phuket/3073/2013(B/Yamagatalineage)-likevirus.Cellculture-orrecombinant-basedvaccinesanA/Wisconsin/67/2022(H1N1)pdm09-likevirus;anA/Darwin/6/2021(H3N2)-likevirus;aB/Austria/1359417/2021(B/Victorialineage)-likevirus;andaB/Phuket/3073/2013(B/Yamagatalineage)-likevirus.WHORecommendsthattrivalentvaccinesforuseinthe2023-2024influenzaseasoninthenorthernhemispherecontainthefollowing:Egg-basedvaccinesanA/Victoria/4897/2022(H1N1)pdm09-likevirus;anA/Darwin/9/2021(H3N2)-likevirus;andaB/Austria/1359417/2021(B/Victorialineage)-likevirus.Cellculture-orrecombinant-basedvaccinesanA/Wisconsin/67/2022(H1N1)pdm09-likevirus;anA/Darwin/6/2021(H3N2)-likevirus;andaB/Austria/1359417/2021(B/Victorialineage)-likevirus.義翹神州InfluenzaVirus-疫苗進(jìn)展一些新的技術(shù)平臺也應(yīng)用到流感疫苗的開發(fā)中，例如病毒載體疫苗、mRNA疫苗等。未來流感疫苗開發(fā)的方向是開發(fā)通用流感疫苗，可以覆蓋不同流感亞型，并可以應(yīng)對流感的快速進(jìn)化。義翹神州UNIVERSALINFLUENZAVACCINETECHNOLOGYLANDSCAPE(byIVR)InfluenzaVirus-疫苗進(jìn)展/10.3390/v14081684/10.3390/v14081684義翹神州InfluenzaVirus-疫苗進(jìn)展義翹神州VaccineNameDeveloper/LocationPlatformR&DStatusPhaseMultimeric-001(M-001)BiondVaxPharmaceuticals(Israel)RecombinantproteinsInactivePhase3QuadrivalentVLP(QVLP)Medicago(Canada)Virus-likeparticles(VLP)InactivePhase3Nano-Flu(qNIV)Novavax(US),EmergentBioSolutions(US)Non-VLPnanoparticlesActivePhase3ModifiedmRNAvaccinePfizer(US),BioNTech(Germany)Nucleicacid-basedActivePhase3mRNA-1010Moderna(US)Nucleicacid-basedActivePhase3FLU-vConserVBioscience(UK),Imutex(UK)RecombinantproteinsActivePhase2deltaFLUVivaldiBiosciences(US)Influenzavirus-basedActivePhase2M2SRFluGen(US)Influenzavirus-basedActivePhase2MVA-NP+M1(VTP-100)Vaccitech(UK)Virus-vectoredInactivePhase2NasoVAXAltimmune(US)Virus-vectoredInactivePhase2VXA-A1.1oraltabletVaxart(US)Virus-vectoredActivePhase2CICVaccineNovavax(US)Non-VLPnanoparticlesActivePhase2OVX836Osivax(France)Non-VLPnanoparticlesActivePhase2mRNA-1020andmRNA-1030Moderna(US)Nucleicacid-basedActivePhase2UNIVERSALINFLUENZAVACCINETECHNOLOGYLANDSCAPE(byIVR)RSV-病毒抗原簡介RSVhastwomajorsubtypes:AandB.TargetsFunctionApplicationFusion(F)glycoproteinFusionandcellentry;HighlyconservativeVaccine,drugs,andimmunodiagnosisGglycoproteinHostcellattachment;HighlyVariableVaccineNucleocapsid(N)EnvelopvirusgenomeVaccine,immunodiagnosis*Thefollowingarethemostfrequentlydevelopedtargetsforvaccine,drug,andimmunodiagnosticdevelopment:義翹神州RSV-疫苗進(jìn)展義翹神州FDA批準(zhǔn)了兩款基于蛋白的疫苗GSK的Arexvy?Pfizer的BRYSVO?

適用范圍：皆為60歲及以上群體。RSV-疫苗開發(fā)面臨的挑戰(zhàn)融合前表位表位?，表位Ⅴ，Quaternary-Dependent融合前后都存在的表位表位Ⅰ，表位Ⅱ，表位Ⅲ，表位Ⅳ抗原設(shè)計twocavity-fillingmodifications(S190FandV207L)foldontrimerizationdomaintwomutations(S155CandS290C)thatformadisulfidebond義翹神州

DOI:

10.1126/science.aav9033Herpesviridae

Viruses-病毒概述是一類雙鏈DNA病毒，總共有100多種，可以分為α、β、γ三大類。其中有以下幾種會感染人類：名稱別名亞科主要感染細(xì)胞感染潛伏部位HHV?1單純皰疹病毒-1（HSV-1）α黏膜上皮皰疹性口腔炎、生殖器皰疹與其他部位的單純皰疹神經(jīng)元HHV-2單純皰疹病毒-2（HSV-2）α黏膜上皮皰疹性口腔炎、生殖器皰疹與其他部位的單純皰疹神經(jīng)元HHV-3水痘-帶狀皰疹病毒

（VZV）α黏膜上皮水痘與帶狀皰疹神經(jīng)元HHV-4EBV病毒、LymphocryptovirusγB細(xì)胞與上皮細(xì)胞EBV關(guān)聯(lián)淋巴增生性疾病、傳染性單核白血球增多癥、鼻咽癌等B細(xì)胞HHV-5巨細(xì)胞病毒

（CMV）β單核球與上皮細(xì)胞類似傳染性單核白血球增多癥的癥狀、網(wǎng)膜炎單核球等HHV-6A與6B玫瑰皰疹病毒βT細(xì)胞等第六癥（小兒急疹）T細(xì)胞等HHV-7βT細(xì)胞等藥物超敏反應(yīng)綜合征、腦病變,偏側(cè)驚厥一偏癱一癲癇綜合征、肝炎、玫瑰糠疹、類似傳染性單核白血球增多癥的癥狀等T細(xì)胞等HHV-8卡波西氏肉瘤皰疹病毒

（KSHV）（屬蛛猴病毒屬）γ淋巴球等卡波西氏肉瘤、原發(fā)性體液淋巴瘤、HHV-8關(guān)聯(lián)淋巴結(jié)增生癥B細(xì)胞義翹神州Herpesviridae

Viruses-病毒抗原簡介Structure,Classification-HerpesViruses

|12thMicrobiology:Chapter10:MedicalVirology病毒表面有多種糖蛋白：gB、gC、gD、gE、gG、gH、gI、gJ、gK、gL、gM和gNgB、gD是大多數(shù)HSV疫苗的靶標(biāo)，因為它對于病毒進(jìn)入宿主細(xì)胞至關(guān)重要義翹神州HSVCandidatenameDeveloperVaccineComponentsandMethodologyDevelopmentalPhaseLive-AttenuatedVaccinesHSV-2ΔNLS(RVX201)SIU-RationalVaccinesLive,attenuatedreplication-competentHSV-2withdeletionofICP0PhaseII-DCNE-HSV-2BlueWillowBiologicsNanoemulsionwithgB2andgD2antigensPre-ClinicalSubunitVaccinesHSV-2trivalentvaccineUniversityofPennsylvaniagC2,gD2,gE2;CpG/alumAdjuvantClinicalGEN-003GenoceagD2(truncated)+ICP4fragment(29.2kD)+MatrixM2AdjuvantCompletedPhaseII(DC)gD2subunitvaccineGlaxoSmithKlinegD2withAS04(dMPL)CompletedPhaseIII(DC)ReplicationDefectiveViralVaccinesCJ2-gD2Non-replicatinggD2dominantnegHSV-2Pre-ClinicalDNAVaccinesCOR-1AdmedusgD2ubiquitintag,codonoptimizedDNAvaccinePhaseIIVCL-HB01/HM01VicalDNAvaccine:gD2+/?UL46/VaxfectinPhaseII(DC)Doi:

10.3389/fmicb.2021.798927*沒有批準(zhǔn)用于預(yù)防HSV感染的疫苗義翹神州Herpesviridae

Viruses-疫苗進(jìn)展Herpesviridae

Viruses-疫苗開發(fā)面臨的挑戰(zhàn)挑戰(zhàn)：減毒活疫苗的主要挑戰(zhàn)之一仍然是疫苗安全性。亞單位疫苗的挑戰(zhàn)在于產(chǎn)生有效、持久的免疫反應(yīng)。皰疹病毒會產(chǎn)生潛伏期，這使疫苗開發(fā)復(fù)雜化，預(yù)防潛伏感染是挑戰(zhàn)。設(shè)計有效的治療性或預(yù)防性疫苗需要對單純皰疹病毒發(fā)病機制和免疫逃避的復(fù)雜性的進(jìn)一步理解。義翹神州整體解決方案及相關(guān)案例分享03義翹神州臨床前研究疫苗開發(fā)整體解決方案產(chǎn)品：重組抗原中和抗體，檢測抗體抗原含量檢測試劑盒抗體滴度檢測試劑盒肽庫細(xì)胞因子檢測試劑盒流式抗體假病毒服務(wù)：細(xì)胞庫檢測（CHO,Vero,HEK293等）病毒清除驗證實驗抗原開發(fā)服務(wù)抗體開發(fā)服務(wù)理化及生物效價評估（滴度、中和等）生產(chǎn)質(zhì)控-疫苗生產(chǎn)工藝的研究；-免疫原性或生物效價；穩(wěn)定性研究；-免疫原性；-疫苗生物效價；產(chǎn)品：重組抗原中和抗體，檢測抗體抗體滴度檢測試劑盒肽庫細(xì)胞因子檢測試劑盒流式抗體假病毒服務(wù)：生物效價評估人源化抗體服務(wù)產(chǎn)品：重組抗原中和抗體，檢測抗體抗體滴度檢測試劑盒肽庫假病毒核酸酶核酸酶殘留檢測試劑盒服務(wù)：生物效價評估人源化抗體服務(wù)理化及生物效價評估（SEC-MALS等）-抗原、抗體、生物效力的檢測；-雜質(zhì)、殘留檢測臨床研究義翹神州特色產(chǎn)品及服務(wù)——流感RecombinantAntigensfor2015-2024InfluenzaVaccineStrainsRecombinantAntigensforEmergingPandemicStrainsWHO推薦-禽流感疫苗株World’sLargestInfluenzaVirusResearchReagentCenter:PanInfluenzaAandBAntibodyagainstHemagglutininorNucleoprotein在線200+抗體廣譜HA、NP抗體應(yīng)用：WB，ELISA，SandwichELISA，HI，MN20+ELISAKit10AntigensHA(HA0,HA1,HA2,HA),NA,NP,M1,M2,NS1,PB1,PB2,PA630+ProteinsHighActivityCoveringMostofHotResearchStrains200+AntibodiesNeutralizingAntibodiesPanAntibodies(BroadSpectrum)60SubtypesH1-H18,N1-N11,InfluenzaB330StrainsVaccineStrainsHPAIStrainsNewlyIdentifiedStrains1,500+Genes,ELISAKitsAllProducedIn-house義翹神州特色產(chǎn)品及服務(wù)——流感更接近天然：流感HA三聚體蛋白Thepurityismorethan95%.TheMWisaround225kDa.SEC-MALSImmobilizedrecombinantHAprotein(Cat:40938-V08H2)

at5μg/mL(100μL/well)canbindRecombinantHumanGalectin-1/LGALS1Protein

(Cat:10290-HNAE),theEC50

is120-350ng/mL.ImmobilizedrecombinantHAProtein(Cat:40938-V08H2)

at1μg/mL(100μL/well)canbindantibodytargetstheHAstemregionofH1N1,theEC50

is4ng/mL-12ng/mL.ActivityInfluenzaAH1N1(A/Victoria/4897/2022)Hemagglutinin/HATrimerProtein(HisTag)(HPLC-verified)義翹神州具有活性驗證數(shù)據(jù)特色產(chǎn)品及服務(wù)——流感BioactiveHAAntigensHA:HemagglutinationActivityH1N1,A/swine/Shandong/1207/2016(Cat:40651-V08H)H7N9,A/Anhui/1/2013

(Cat:40103-V08B)HA:BindingActivitytoSialicAcidBLI:KD=18.4nM(Cat:40116-V08B)NA：EnzymaticActivityH1N1,A/Brisbane/02/2018(Cat:40767-V08B)MeasuredNA’sabilitytocleave2'-(4-Methylumbelliferyl)-α-D-N-acetylneuraminicacid.Thespecificactivityis40296pmoles/min/μg.H1N1,A/Brisbane/02/2018(Cat:40569-V08B)MeasuredNA’sabilitytocleave2'-(4-Methylumbelliferyl)-α-D-N-acetylneuraminicacid.Thespecificactivityis29781pmoles/min/μg.義翹神州特色產(chǎn)品及服務(wù)——流感流感廣譜Hemagglutinin/HA抗體H1N1廣譜HA抗體：86001-RM01H3N2廣譜HA抗體：11056-MM03InfluenzaB廣譜HA抗體：11053-R004編號蛋白貨號亞型毒株疫苗株年份86001-RM0111056-MM0311053-R004140938-V08HH1N1A/Victoria/4897/20222023-2024+++--240940-V08HA/Wisconsin/67/20222023-2024+++--340787-V08H(A/Wisconsin/588/2019)/(A/Victoria/2570/2019)2022-2023+++--140859-V08BH3N2A/Darwin/9/20212023-2024,2022-2023++++++-240868-V08BA/Darwin/6/20212022-2023++++++-340789-V08HA/Cambodia/e0826360/20202021-2022++++++-140498-V08BInfluenzaBB/PHUKET/3073/20132015-2024--+++240862-V08HB/Austria/1359417/20212023-2024,2022-2023--+++340722-V08HB/Washington/02/20192022-2023,2021-2022,2020-2021--+++廣譜流感HA抗體義翹神州特色產(chǎn)品及服務(wù)——流感HA試劑盒（經(jīng)濟(jì)型+即用型），滿足不同檢測通量需求NP經(jīng)濟(jì)型試劑盒，靈活搭配不同標(biāo)準(zhǔn)品，滿足不同毒株定量需求貨號抗原種屬分子線性范圍(pg/ml)靈敏度(pg/ml)KIT11055H1N1HA31.25-200014.71KIT11684H1N1HA62.5-400018.5KIT11056H3N2HA781.25-50000263.49KIT11714H4N6HA62.5-400016KIT11048H5N1HA125-800089.7KIT40103H7N9HA15.6-10004.9KIT40104H7N9HA15.6-10003KIT11229H9N2HA78.13-50006.9KIT11053InfluenzaBHA109.38-700025.54貨號抗原種屬分子線性范圍(pg/ml)靈敏度(pg/ml)SEK001H1N1HA31.25-200031.25SEK11684H1N1HA28.13-400028.13SEK11056H3N2HA390.63-25000390.63SEKA002H5N1HA125-8000125SEK40103H7N9HA62.5-400062.5SEK11229H9N2HA156-10000156SEK11053InfluenzaBHA78.13-500078.13SEK004H1N1NP62.5-400062.5SEK006H3N2NP234.4-15000234.4SEK005InfluenzaBNP39.06-250039.06SEK007InfluenzaBNP156.25-8000156.25即用型經(jīng)濟(jì)型義翹神州DOI:3389.2020/fimmu.00431.案例展示：本文中應(yīng)用義翹神州的多種亞型的重組流感HA蛋白進(jìn)行了通用疫苗的交叉保護(hù)驗證實驗。流感疫苗研究中的應(yīng)用——通用疫苗開發(fā)義翹神州流感疫苗研究中的應(yīng)用——抗原含量檢測義翹神州的流感NA抗體（Cat：11058-MM07）檢測Sf9昆蟲細(xì)胞表達(dá)的NA-VLPs的表達(dá)水平。案例展示：Westernblot檢測pIZ-NA質(zhì)粒轉(zhuǎn)染的Sf9細(xì)胞的NA蛋白表達(dá)DOI:

10.1007/s12033-022-00519-8義翹神州流感疫苗研究中的應(yīng)用——穩(wěn)定性研究，HA含量檢測采用義翹神州流感HA配對抗體套裝（Cat：SEK002，升級后貨號Cat：SEKA002）定量檢測HA含量。證實凝膠包封有助于改善疫苗熱穩(wěn)定性，降低運輸經(jīng)濟(jì)成本。案例展示：DOI:

10.1126/sciadv.abo0502義翹神州特色產(chǎn)品及服務(wù)——RSVSinoBiologicalhasdevelopedacomprehensivecollectionofRSV-relatedreagentsforviralresearch(18antigens,7antibodies,80+ELISAKits,andcDNAs)thatcoverRSVAandBfromover5strains.Cat#MoleculeTagStrain40830-V08HRSV-GC-HisstrainA240829-V08HRSV-GC-Hisstrain1853740831-V08BRSV-FC-Hisstrainlong40832-V08BRSV-FC-Hisstrain1853740627-V08BRSV-FC-HisRSVA/Homosapiens/USA/LA2_17/201340628-V08BRSV-FC-HisRSVB40037-V08BRSV-FC-HisRSVA,strainRSS-211049-V08BRSV-FC-HisRSVA,strainA2PartialRecombinantRSVAntigenListEffectivemicroneutralizationactivity(Cat:11049-R338)Anti-RSVFNeutralizingAntibodyRSVA-A2strainpseudovirusinfectioninVerocellswasinhibitedbyFproteinantibody.TheIC50

ofantibodyis0.6-2.3μg/mLAnti-RSV-FrabbitmonoclonalantibodyWesternBlotAssayforRSV-Fantigendetection(Cat:11049-R302)Lane1:RSV-FProtein(ECD)(Cat:11049-V08B)Lane2:RSV-FProtein(StrainRSS-2)(Cat:40037-V08B)Lane3:RSV-FProtein(aa1-525)(Cat:40628-V08B)Lane4:RSV-FProtein(aa1-526)(Cat:40627-V08B)Lane5:RSV-FProtein(A,strainLong)(Cat:40831-V08B)Lane6:RSV-F0Protein(B,strain18537)(Cat:40832-V08B)義翹神州特色產(chǎn)品及服務(wù)——RSV穩(wěn)定的重組RSV-preF蛋白Humanrespiratorysyncytialvirus(RSV)(A2)PrefusionglycoproteinF/RSV-preFProtein(Cat:

11049-VNAS)Thepurityismorethan95%.TheMWisaround170kDa.SEC-MALSActivityPre-F抗原表位是否檢測表位Ⅱ√表位Ⅴ√表位?√Quaternary-Dependent√CanbindantibodywhichtargetsantigenicsiteII,theEC50

is0.5ng/mL-1.7ng/mL.CanbindantibodywhichtargetsantigenicSite?,theEC50

is0.45ng/mL-1.35ng/mLCanbindantibodywhichtargetsantigenicSiteV,theEC50

is0.05ng/mL-0.15ng/mL義翹神州RSV疫苗研究中的應(yīng)用——血清滴度檢測Cat：11049-V08BCat：40830-V08HRSV疫苗研究中，將義翹神州的RSV-G重組蛋白用做ELISA檢測的包被抗原，檢測血清中RSVA2病毒特異性抗體的滴度。doi:10.1016/j.vaccine.2014.08.045.在一項DNA疫苗的研究中，利用義翹神州開發(fā)的RSV-F重組蛋白進(jìn)行疫苗免疫后血清抗體滴度的檢測。doi:10.1016/j.vaccine.2017.04.008.案例展示：義翹神州特色產(chǎn)品及服務(wù)——皰疹病毒科貨號種屬分子表達(dá)宿主40907-V08HVZVVZV-gEHEK293Cells40958-VNASVZVVZV-gBCHOStableCellsCT125-VNASVZVgH&gLCHOStableCells40935-V08BHSV2gBBaculovirus-InsectCells40936-V08BHSV2gDBaculovirus-InsectCells40936-V08HHSV2gDHEK293Cells40957-V08H1HSV2gCHEK293Cells40937-V08BHSV2gEBaculovirus-InsectCells40373-V08BEBVEBV-gp350Baculovirus-InsectCells40373-V08HEBVEBV-gp350HEK293CellsCT124-V0825HEBVgH&gLHEK293Cells10202-V02H1CMVgBHEK293Cells10202-V02H2CMVgBHEK293Cells10202-V08H1CMVgBHEK293Cells10202-VCCH1CMVgBHEK293Cells質(zhì)量驗證HSV2(strain333)gDProtein(Cat:

40936-V08H)ImmobilizedRecombinantHumanCD111/Nectin-1/PVRL1Protein(FcTag)(Cat:11611-H02H)at2μg/ml(100μl/well)canbindRecombinantHSV2(strain333)gDProtein(ECD,HisTag)(Cat:40936-V08H),theEC50

is30-100ng/mL.VZV(strainOkavaccine)GlycoproteinBProtein(Cat:

40958-VNAS)Thepurityismorethan95%.TheMWisaround276kDa.義翹神州Omicron抗體最快速度